Clinical Trial Update: Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a bivalent vaccine using the OPT-821 adjuvant with oral beta-glucan for high-risk neuroblastoma. The Phase 1/2 study is active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Beta Glucan (beta-glucan)
• OPT-821

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING